Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of
antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector …

Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health …

Broadly neutralizing antibodies are an important treatment for individuals with coronavirus
disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 …

Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum
neutralizing antibody (nAb) titers correlate with protection against coronavirus disease 2019 …

Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global
health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 …

The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS …

Efficacious interventions are urgently needed for the treatment of COVID-19. Here, we report
a monoclonal antibody (mAb), MW05, with SARS-CoV-2 neutralizing activity by disrupting …

Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-
19, little is known about their mechanism (s) of action or effective dosing windows. We report …

Monoclonal antibodies (mAbs) have revolutionized the treatment of several human
diseases, including cancer and autoimmunity and inflammatory conditions, and represent a …